Breaking Finance News

Zacks Investment Research downgraded Hill-Rom Holdings, Inc. (NYSE:HRC) to Hold in a report released today.

Zacks Investment Research has downgraded Hill-Rom Holdings, Inc. (NYSE:HRC) to Hold in a report released on 5/16/2017.

Previously on 05/02/2017, Barclays Capital reported about Hill-Rom Holdings, Inc. (NYSE:HRC) raised the target price from $75.00 to $80.00. At the time, this indicated a possible upside of 0.06%.

Yesterday Hill-Rom Holdings, Inc. (NYSE:HRC) traded -0.38% lower at $73.04. The company’s 50-day moving average is $72.38 and its 200-day moving average is $62.77. The last stock close price is up 16.36% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 201,399 shares of the stock were exchanged, down from an average trading volume of 497,654

See Chart Below

Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. has a 52 week low of $46.91 and a 52 week high of $77.37 with a P/E ratio of 31.55 The company’s market cap is currently $0.

About Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company's products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.